Compare HUBS & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HUBS | NTRA |
|---|---|---|
| Founded | 2005 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.8B | 27.0B |
| IPO Year | 2014 | 2015 |
| Metric | HUBS | NTRA |
|---|---|---|
| Price | $377.40 | $244.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 30 | 16 |
| Target Price | ★ $626.87 | $227.69 |
| AVG Volume (30 Days) | 833.8K | ★ 1.7M |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,987,698,000.00 | $2,116,676,000.00 |
| Revenue This Year | $20.84 | $32.77 |
| Revenue Next Year | $16.03 | $16.51 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 19.21 | ★ 38.17 |
| 52 Week Low | $344.41 | $125.38 |
| 52 Week High | $881.13 | $245.59 |
| Indicator | HUBS | NTRA |
|---|---|---|
| Relative Strength Index (RSI) | 41.61 | 80.03 |
| Support Level | $364.00 | $233.67 |
| Resistance Level | $381.70 | $240.18 |
| Average True Range (ATR) | 13.79 | 7.39 |
| MACD | 4.30 | 0.68 |
| Stochastic Oscillator | 67.68 | 97.49 |
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.